Cellular and T cell engager Immunotherapy
Pharmacokinetics (PK) and immunogenicity of linvoseltamab in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in LINKER-MM1
Glenn Kroog, n/a
Clinical Sciences
Regeneron Pharmaceuticals, Inc, United States